Overview
Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer
Status:
Completed
Completed
Trial end date:
2021-02-15
2021-02-15
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
Evaluating efficacy and safety of bevacizumab when combined with chemotherapy (carboplatin and Paclitaxel ) in treatment of patient with metastatic triple negative breast cancerPhase:
Phase 2Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Assiut UniversityTreatments:
Bevacizumab
Criteria
Inclusion Criteria:1. Female patient firstly diagnosed with metastatic TNBC or after adjuvant treatment OF
TNBC by immune histochemistry and biopsy
2. Age >18 Y
3. Performance status (PS ) 0-2
4. Did not have any bleeding disorders.
5. Receive only one line of chemotherapy in adjuvant ttt
Exclusion Criteria:
1. Male patient
2. PS >2
3. Uncontrolled HPTN
4. Have history of bleeding disorders
5. Receive > one line of chemotherapy
6. Have other type of malignancy